1. Inpatient Initiation of Oral Treprostinil in an Academic Medical System.
- Author
-
Hohlfelder B, Tonelli AR, Heresi GA, Bair N, Rahaghi FF, and Bauer SR
- Subjects
- Academic Medical Centers, Administration, Oral, Adult, Aged, Antihypertensive Agents adverse effects, Drug Substitution, Epoprostenol administration & dosage, Epoprostenol adverse effects, Female, Humans, Male, Middle Aged, Ohio, Pulmonary Arterial Hypertension diagnosis, Pulmonary Arterial Hypertension physiopathology, Pulmonary Artery physiopathology, Retrospective Studies, Treatment Outcome, Young Adult, Antihypertensive Agents administration & dosage, Arterial Pressure drug effects, Epoprostenol analogs & derivatives, Inpatients, Pulmonary Arterial Hypertension drug therapy, Pulmonary Artery drug effects
- Abstract
Purpose: Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to parenteral therapy. However, few data are available to guide these transitions in inpatients. The purpose of this analysis is to describe the inpatient initiation of oral treprostinil at an academic medical system., Methods: This is a retrospective cohort analysis of patients newly initiated on oral treprostinil at Cleveland Clinic Heath System from 2015 to 2017. Demographic information regarding pulmonary arterial hypertension (PAH) history and previous PAH therapies were recorded. Outcomes evaluated included doses of oral treprostinil utilized, adverse effects related to therapy, and measures of clinical and functional status before and after the initiation of oral treprostinil., Results: Overall, 29 patients were prescribed oral treprostinil, of which 15 patients were included in the analysis. Common reasons for initiation of oral treprostinil included disease progression (6, 40%) and patient desire (4, 25%). The median duration of transition/initiation of oral treprostinil was 4 days (range, 3-11 days). Median daily dose of oral treprostinil on day 1 of initiation was 2 mg (0.25-4 mg). By day 7, median daily dose was 15 mg (0.75-27.75 mg). Common adverse effects related to therapy were gastrointestinal (7, 47%) and headache (4, 27%). No patients required discontinuation of oral treprostinil due to adverse effects within 90 days of initiation., Conclusion: Inpatient initiation/transition to oral treprostinil was relatively well tolerated. Future studies should evaluate clinical outcomes surrounding the transitioning to oral treprostinil.
- Published
- 2020
- Full Text
- View/download PDF